For Q1 FY 2026-27

Investor Presentation - Q1FY27 - Revenue 15.4bn, EBITDA 1.59bn, EBITDA margin 10.3%, PAT 0.67bn - EBITDA margin declined from 17.4% in Q4FY26 to 10.3% in Q1FY27 - Finance costs increased slightly to 328m; forex gain of 198m improved results - API segment shows diverse product mix with focus on anti-diabetic, anti-infective - Formulations sales concentrated in Africa and other export markets - Strategic focus on R&D, capacity expansion, regulatory compliance, and cost optimization - Company aims to reduce China dependence and increase asset turnover - Maintains global regulatory accreditations including US FDA and EU GMP - Net profit declined from 1.89bn in Q4FY26 to 0.67bn in Q1FY27